Top of page
Health

Alzheimer’s drug candidates reverse broader aging, study shows

Elderly lonely woman with Alzheimer

In mouse models of Alzheimer’s disease, the investigational drug candidates known as CMS121 and J147 improve memory and slow the degeneration of brain cells. Now, Salk researchers have shown how these compounds can also slow aging in healthy older mice, blocking the damage to brain cells that normally occurs during aging and restoring the levels of specific molecules to those seen in younger brains.

The research, published last month in the journal eLife, suggests that the drug candidates may be useful for treating a broader array of conditions and points out a new pathway that links normal aging to Alzheimer’s disease.

“This study further validated these two compounds not only as Alzheimer’s drug candidates but also as potentially more widely useful for their anti-aging effects,” says Pamela Maher, a senior staff scientist at Salk and a co-corresponding author of the new paper.

Old age is the biggest risk factor for Alzheimer’s disease—above the age of 65, a person’s risk of developing the disease doubles about every five years. However, at a molecular level, scientists aren’t sure what occurs in the brain with aging that contributes to Alzheimer’s.

“The contribution of old age-associated detrimental processes to the disease has been largely neglected in Alzheimer’s disease drug discovery,” says Antonio Currais, a Salk staff scientist and first author of the new paper.

You might also like

doctor with a patient doctor with a patient

NHS collaborates to create sensory-friendly GP surgeries for autistic patients

The National Health Service (NHS) has partnered with a group…

Human Brain Human Brain

Brain injuries require lifelong management: Study

More than 1.5 million Americans suffer a traumatic brain injury…

Disabled woman in wheelchair with assistant walking in garden Disabled woman in wheelchair with assistant walking in garden

Disability service provider prioritised profit over participants health and safety

The Royal Commission has published a Commissioners’ report on Public…

Adult and child hands holding encephalography brain paper cutout, epilepsy Adult and child hands holding encephalography brain paper cutout, epilepsy

Monash funds $3m for epilepsy drug trial

Epilepsy affects over 150,000 Australians, and 50 million globally, with…